Orbimed Advisors Llc Insider Buy Transaction
The insider of Sientra Inc (NASDAQ:SIEN)
7.01 -0.20 -2.77%
, Orbimed Advisors Llc is in the stock market news today. It was made public in a public report filled by Orbimed Advisors Llc and submitted to the (SEC) on October 09, 2015, the insider unloaded 666,609 shares from the firm having an approx. value of $4,788,048 US Dollars. The insider shares average price was $7.2. The likelihood that this trade remains unseen is nil due to the large amount of cash involved. Today, Orbimed Advisors Llc owns 19,885 shares which are equivalent to roughly 10%+ of Sientra Inc’s market cap (share price times the number of shares outstanding).
Sientra Inc Stock Rating, Sentiment and Fundamentals
Because the deal, Orbimed Advisors Llc did is large, it could very well indicate that the insider remains pessimistic regarding the Company’s future, as well as the stock price rising. Not only that but four of world’s professional security analysts, expect the current fiscal year’s earnings for each share at $-1.15, with an overall year-on-year growth of 20.00%. This would give it a NaN PE ratio.
Rating & Sentiment
PsychSignal Social:
SELL
Analysts Rating:
BUY
Hedge Funds Sentiment:
BUY
Stock Fundamentals
Earnings + FCF Trend:
BUY
Sector/Industry Macro:
BULLISH
Valuation Models:
-
Technical Analysis
ST Trend:
DOWN
MT Trend:
DOWN
LT Trend:
DOWN
OctaFinance Rating*:
SELL
* Read How Our Stock Ratings System Works
Our equity traders have no choice but to rate the stock a sell and not just because of Orbimed Advisors Llc’s stock sell, but also our back-tested stocks trend-following model as presented on the chart below. Sientra Inc’s share is in a bearish trend, diving around 57.33% over the last 200 days.
Price Chart of Sientra NASDAQ:SIEN Stock
Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations
As the professional David Tepper, one of the hedge fund legends, stated, highest risk-adjusted returns are made through a mix of fundamental and technical analysis.
Hedge Funds Ownership
Recently released 13F public filings data disclose 53 institutional investors holded Sientra Inc. The institutional ownership of the company in Q2 2015 is high, at 81.55% of the shares outstanding. They increased by 29,627 the total shares they hold. As of that quarter these institutional and hedge funds owned 14.63 million shares.
Amongst them, four have this stock in their Top 10. Some of them are: Abingworth Llp, Clarus Ventures Llc, Pura Vida Investments Llc, Drill Craig A.
Abingworth Llp had the greatest investment with ownership of 2.20 million shares as of Q2 2015 for 25.03% of the fund’s portfolio. Clarus Ventures Llc is another bullish institutional manager owning 2.73 million shares of the company or 30.30% of their stocks portfolio. In addition The New York-based fund Pura Vida Investments Llc have 2.87% of their stock portfolio invested in the company for 241,402 shares. The New York-based fund Drill Craig A disclosed it had acquired a stake worth 1.46% of the fund’s stock portfolio in Sientra Inc. Mitchell Blutt’s Consonance Capital Management Lp is also very optimistic about the company’s stock, possessing 132,135 shares or 0.33% of their stock portfolio.
Sientra NASDAQ:SIEN Company Profile
Sientra, Inc. is a medical aesthetics company. The company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 150 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. The Company offers a range of breast implants, including anatomically-shaped textured, round textured and round smooth. It also offers a line of breast tissue expanders, most of which are marketed as ACX, in 25 different shapes and sizes that include single and double chamber tissue expanders. In addition, it offers a range of other aesthetic products, including: body contouring and other implants; silicone elastomer oval carving blocks; scar management specialty products; temporary, single-use, saline-filled breast sizers, and non-breast tissue expanders.
Company Website: Sientra
Now its market capitalization is: $105.05 million and it has 14.57 million outstanding shares. Today it has 98.52% shareholders and the institutional ownership stands at 98.52%. The firm has 95 employees. Sientra Inc was founded in Delaware on 2003-08-29. The stock closed at $7.01 yesterday and it had average 2 days volume of 72429 shares. It is down from the 30 days average shares volume of 135502. Sientra Inc has a one year low of $6.95 and a 52weeks high of $26.51. The current price is below the 200 days SMA. Sientra Inc last issued its quarterly earnings information on 08/12/2015. The company reported -0.2 EPS for the quarter, above the consensus estimate of -0.35 by 0.15. The company had a revenue of 14.21 million for 6/30/2015 and 12.43 million for 3/31/2015. Therefore, the revenue was 1.77 million up.
Orbimed Advisors Llc is also director of Pronai Therapeutics Inc, Intercept Pharmaceuticals Inc, Pieris Pharmaceuticals, Inc., Glaukos Corp, Anthera Pharmaceuticals Inc, Amarin Corp PlcUk, Nxstage Medical, Inc., Biodel Inc, Insulet Corp, Volcano Corp, Avanir Pharmaceuticals, Inc., Given Imaging Ltd, Euthymics Bioscience Inc, Orphan Medical Inc, Memory Pharmaceuticals Corp, 10 percent owner of Relypsa Inc, Mirati Therapeutics, Inc., Otonomy, Inc., Loxo Oncology, Inc., Roka Bioscience, Inc., Response Biomedical Corp, Ambit Biosciences Corp, Supernus Pharmaceuticals Inc, Complete Genomics Inc, Pacira Pharmaceuticals, Inc., Chemocentryx, Inc., Athersys, Inc / New, Kun Run Biotechnology, Inc., Aryx Therapeutics, Inc., Cryocor Inc, Aerogen Inc, Lifecell Corp, Orthovita Inc.
* These shares are held of record by OrbiMed Private Investments III – LP (“OPI III”). OrbiMed Capital GP III LLC (“GP III”) is the general partner of OPI III – and OrbiMed Advisors LLC (“Advisors”) is the managing member of GP III. Samuel D. Isaly (“Isaly”) – a natural person – is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships – GP III – Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to have beneficial ownership over such securities.
* These shares are held of record by OrbiMed Associates III – LP (“Associates III”). Advisors is the general partner of Associates III. Isaly is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships – Advisors and Isaly may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities.
* This report on Form 4 is jointly filed by GP III – Advisors – and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934 – as amended (the “Exchange Act”) – except to the extent of its or his pecuniary interest therein – if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act – or for any other purpose.
The post Inside Trade: Orbimed Advisors Llc Sold 666,609 Shares of Sientra Inc (NASDAQ:SIEN) appeared first on Octafinance.